Keyword: Opdivo

After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.

Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.

Nektar’s much-anticipated data from a study pairing its NKTR-214 with Bristol-Myers Squibb’s Opdivo have resulted in a lot of head-scratching.

Frances Rena Bahjat, BMS’ former director of in vivo studies, joined Apexigen in a newly created role.

The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.

Jounce shares fall after publication of an ASCO abstract giving initial data from a trial of its first-in-class ICOS inhibitor JTX-2011.

A pilot showed X4’s anti-PD-1 combination spurred activity in patients that didn’t respond to Opdivo treatment alone, with a drug bought from Sanofi.

Management took the action after technical issues slowed progress of the inducible adenoviral vector.

Eli Lilly is acquiring Armo Biosciences and its lead asset, a PEGylated form of the cytokine IL-10, for $1.6 billion.

Incyte is downgrading two pivotal epacadostat-Keytruda trials to phase 2 studies and backing away from six other late-stage tests of its IDO drug.